Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 10/20 | 0.49 |
| ▸ | CTSS | P25774 | 5/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68450 | 1.00 | CA1 (0.67) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL969077 | 1.00 | CA1 (0.67) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL4771470 | 0.88 | CA1 (0.61) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL16970604 | 0.88 | CA1 (0.56) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL8961360 | 0.88 | CA1 (0.56) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL272148 | 0.88 | CA1 (0.56) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL168390 | 0.86 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL16970732 | 0.86 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL7356326 | 0.86 | CA1 (0.67) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL14265317 | 0.85 | CA1 (0.53) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4501942-A1 | PEPTIDOMIMETICS WITH ANTIVIRAL ACTIVITY | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024216154-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20230072397-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-09 | — | — | US | disclosed |
| US-20220000844-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2022-01-06 | — | — | US | disclosed |
| CN-113825748-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3891157-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3214086-B1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND | UBE INDUSTRIES (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | UBE INDUSTRIES, LTD. (JP) | 2021-04-06 | — | — | US | disclosed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| EP-1660085-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| WO-2005013986-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004089362-A1 | 2-CYANOPYRROLES AND THEIR ANALOGUES AS DDP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-1144396-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | Bayer Corporation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | MAP3K6, MAP3K5, MAP4K2 | CA1 4861/4885CA2 3954/4885CA7 4771/4885 |
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | CA1 2561/4885CA2 866/4885CA7 3148/4885 |
| US-20220000844-A1 | 4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | TRPV1, SCN7A, SCN1A | CA1 2378/4885CA2 496/4885CA7 891/4885 |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | CA1 4399/4885CA2 3091/4885CA7 4262/4885 |
| US-20230072397-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | CA1 4525/4885CA2 2151/4885CA7 1619/4885 |
| US-10968238-B2 | Substituted dihydropyrrolopyrazole compound | QDPR, CYP2D6, KCNJ11 | CA1 3728/4885CA2 1586/4885CA7 4226/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | CA1 4633/4885CA2 4302/4885CA7 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.